The First Affiliated Hospital of Zhejiang University School of Medicine recently held the clinical launch meeting for an expansion of the investigator-initiated clinical trial (IIT) to include relapsed or refractory indolent B-cell non-Hodgkin lymphoma (r/r B-iNHL) as a new indication for Leman Biotech’s metabolically armed CD19 CAR-T therapy, Meta10-19 therapy. The clinical protocol focuses on preparing allogeneic CAR-T cells using fully matched or partially matched donor lymphocytes, aiming to provide more patients with timely and high-quality CAR-T therapy.
